Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Search
Drug Profile

Elasomeran - Moderna Therapeutics/National Institute of Allergy and Infectious Diseases

Alternative Names: COVID-19 Vaccine Moderna; Moderna COVID-19 Vaccine; mRNA-1273; mRNA-1273 SARS-CoV-2 vaccine; SARS-CoV-2 RNA vaccine - Moderna Therapeutics; SARS-CoV-2… See more

Latest Information Update: 26 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Moderna Therapeutics; National Institute of Allergy and Infectious Diseases
  • Developer Moderna Therapeutics; National Institute of Allergy and Infectious Diseases; Takeda
  • Class COVID-19 vaccines; RNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed COVID 2019 infections
  • Phase III Human papillomavirus infections

Most Recent Events

  • 17 Sep 2024 Health Canada approves elasomeran for the KP.2 variant of COVID-19 infections (In infants, In children, In adolescents, In adults, In the elderly, Prevention) in Canada (IM)
  • 02 Sep 2024 Taiwan Food & Drug Administration (FDA) approves an updated formulation of Elasomeran for COVID-2019 infections (In adolescents, In children, In the elderly, In infants, Prevention, In adults) in Taiwan (IM)
  • 23 Aug 2024 Japan's Ministry of Health, Labour and Welfare approves Elasomeran for SARS-COV-2 Variant JN.1 treatment of COVID-2019 infections in Japan

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days

New Timelines Chart

We recently added a timeline chart on all drug profiles. You can choose the indication from the drop down menu near the top. The chart will show the time the drug spent in different phases as it progressed through development for that indication. The end result is a Gantt style chart illustrating how long the drug took in each phase. This new chart takes advantage of our longitudinal pipeline data which we have stored every month since 2004. Please use the thumbs up/down buttons to let us know your opinion about this new feature.